| Program Code | Indication | Mechanism | Phase | Region | Status |
|---|---|---|---|---|---|
| AZT-1042 | Metastatic Pancreatic Cancer | KRAS G12C Inhibitor | Phase III | Global | Enrolling |
| AZT-2118 | Multiple Sclerosis | Selective S1P Receptor Modulator | Phase III | EU/US | Topline Q3 2026 |
| AZT-3305 | Neuromuscular Atrophy | Antisense Oligonucleotide | Phase II | US | Dose Expansion |
| AZT-0089 | Relapsing-Remitting Crohn's | Anti-IL23 Monoclonal Ab | Phase I | Global | POC Study |
| AZT-4501 | Generalized Anxiety Disorder | Allosteric GABA-A Modulator | Approved | EMA/FDA | Commercialized |
| AZT-1190 | Advanced Melanoma | Bispecific T-cell Engager | On Hold | US | Portfolio Review |
Targeting solid tumors and hematologic malignancies through novel inhibitors, immunotherapies, and combination regimens.
Advancing treatments for neurodegenerative diseases, CNS disorders, and psychiatric conditions using blood-brain barrier penetrant platforms.
Modulating immune responses in autoimmune diseases, inflammatory bowel conditions, and allergic pathways.
Precision gene therapies, enzyme replacements, and orphan drug development for underserved patient populations.
Former VP of Global Clinical Development at Novartis. 20+ years in oncology and immunology drug development.
PhD in Molecular Pharmacology. Pioneered Zenth's AI-driven target discovery platform and translational pipeline.
Led FDA/EMA approvals for 12 biologics. Expert in global regulatory strategy and quality compliance.
Spearheads multinational trial execution, site management, and patient recruitment optimization.
Partner With Our Therapeutics Division
Explore collaboration opportunities, access our clinical trial database, or connect with our medical affairs team.